The effect of bupivacaine on breathing and pain after bariatric surgery

The effect of local/intraperitoneal Bupivacaine on respiratory factors and pain management after bariatric surgery

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221110056459N2

Enrollment

120

Registered

2024-11-15

Start date

2024-11-21

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity.

Interventions

Intervention 1: Control group: Obese patients who will undergo bariatric surgery without receiving bupivacaine. Intervention 2: Intervention group: Obese patients who will be injected with bupivacaine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients aged 18-65 yearsPatients with morbid obesity (body mass index >40 in people without underlying disease or >35 in patients with chronic underlying disease such as type 2 diabetes or cardiovascular disease and are candidates for bariatric surgery)

Exclusion criteria

Exclusion criteria: Hypersensitivity to bupivacaine

Design outcomes

Primary

Measure	Time frame
Pain and respiratory condition after surgery. Timepoint: The day after the operation. Method of measurement: In order to check respiratory factors after surgery, spirometry is used and Wong-Bakers Visual Analog Scale is used to evaluate patients' pain.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Mehrabi

Shahid Beheshti University of Medical Sciences

dralirezamehrabi63@gmail.com+98 21 23515

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026